| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Revenue | ||||||
Research and development collaborations (note 9) | ||||||
29,544 | 53,019 | 51,762 | 11,009 | |||
Operating expenses: | ||||||
Research and development, net of government grants and credits | ||||||
115,900 | 56,926 | 41,144 | - | |||
Research and development | ||||||
- | - | - | 36,816 | |||
Government grants and credits | ||||||
- | - | - | 1,265 | |||
Net research and development | ||||||
- | - | - | 35,551 | |||
General and administrative | ||||||
64,177 | 29,457 | 18,550 | 12,554 | |||
Impairment on acquired IPR&D (note 6) | ||||||
768 | - | 1,536 | 768 | |||
Total operating expenses | ||||||
180,845 | 86,383 | 61,230 | 48,873 | |||
Loss from operations | ||||||
-151,301 | -33,364 | -9,468 | -37,864 | |||
Other income (expense): | ||||||
Interest and other expense | ||||||
- | - | - | 950 | |||
Change in fair value of warrant liabilities | ||||||
- | - | - | 808 | |||
Accretion expense | ||||||
- | - | - | 576 | |||
Gain on equity investment, net | ||||||
- | - | - | 79 | |||
Interest and other income | ||||||
6,022 | 2,638 | 743 | 308 | |||
Other income (expenses), net (note 10) | ||||||
-740 | -3,659 | -1,237 | - | |||
Foreign exchange (loss) gain | ||||||
- | - | - | 927 | |||
Total other income (expense), net | ||||||
5,282 | -1,021 | -494 | -1,020 | |||
Loss before income taxes | ||||||
-146,019 | -34,385 | -9,962 | -38,884 | |||
Current income tax recovery (expense) | ||||||
- | - | - | 430 | |||
Deferred income tax recovery | ||||||
- | - | - | -5,505 | |||
Income tax expense | ||||||
-582 | 2,171 | 444 | - | |||
Net loss and comprehensive loss | ||||||
-145,437 | -36,556 | -10,406 | -33,809 | |||
Net loss per common share (note 4): | ||||||
Basic | ||||||
-3.83 | -1.26 | -0.51 | -2.65 | |||
Diluted | ||||||
-3.83 | -1.26 | -0.64 | -2.65 | |||
Weighted-average common shares outstanding (note 4): | ||||||
Basic | ||||||
38,022 | 29,089 | 21,249 | 12,736 | |||
Diluted | ||||||
38,022 | 29,089 | 21,321 | 12,736 | |||